1. Home
  2. SNT vs DTIL Comparison

SNT vs DTIL Comparison

Compare SNT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$3.87

Market Cap

95.2M

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$3.79

Market Cap

97.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
DTIL
Founded
1965
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.2M
97.7M
IPO Year
1993
2019

Fundamental Metrics

Financial Performance
Metric
SNT
DTIL
Price
$3.87
$3.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
32.5K
192.7K
Earning Date
11-25-2025
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
257.88
N/A
EPS
0.21
N/A
Revenue
$37,837,000.00
$698,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$34.30
P/E Ratio
$18.26
N/A
Revenue Growth
9.82
N/A
52 Week Low
$2.57
$3.53
52 Week High
$5.34
$8.82

Technical Indicators

Market Signals
Indicator
SNT
DTIL
Relative Strength Index (RSI) 39.91 34.15
Support Level $3.70 $3.53
Resistance Level $4.01 $4.10
Average True Range (ATR) 0.25 0.25
MACD -0.07 -0.02
Stochastic Oscillator 21.18 7.41

Price Performance

Historical Comparison
SNT
DTIL

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Share on Social Networks: